Additional bipolar indication for Seroquel

Seroquel and Seroquel XL (quetiapine) have been approved for the treatment of major depressive episodes in adults with bipolar disorder, in addition to the products' existing indications for schizophrenia and manic episodes. The new indication, for which the maximum daily dose is 600mg, carries a black triangle to indicate that all adverse events should
be reported.

View Seroquel drug record

Further information: AstraZeneca

To sign up for the MIMS monthly news update, register at

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...